February 4, 2022 A potential new cause of the autoimmune disease multiple sclerosis (MS) was discovered by researchers partly funded by the Lupus Research Alliance. Published in the prestigious journal Nature, the study results provide strong evidence that a virus can trigger the development of MS. The LRA invested in this work to help understand […] READ MORE
January 27, 2022 NEW YORK, NY. January 27 — The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT) announced two major initiatives to address underrepresentation of minorities in clinical trials and in the scientific research profession: Project CHANGE by LT and the Diversity in Lupus Research Program. The organization has tackled these […] READ MORE
November 15, 2021 The Lupus Research Alliance (LRA) supports research into causes and mechanisms of lupus, and identification of targets supporting the development of new therapies or cures for lupus patients. At this year’s meeting of the American College of Rheumatology (ACR), 17 LRA-funded researchers presented their work to share discoveries with the thousands of […] READ MORE
November 9, 2021 Results of clinical trials testing many existing and potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2021, November 3-9. Bringing you the most relevant news for our lupus community, following are summaries of key research presented at the meeting: New Data on Approved Lupus Treatments […] READ MORE
August 18, 2021 Many lupus patients are at risk for COVID-19 infection because of treatment with corticosteroids and other immunosuppressive medications and will be eligible for booster vaccination. However, there are large gaps in our understanding of who will benefit from the booster vaccines, what strategies will improve response to the vaccine and the best […] READ MORE
June 8, 2021 The annual European Congress of Rheumatology (EULAR 2021) brought much good news of potential new treatments for systemic lupus erythematosus (SLE). Following are highlights: Rituximab Plus Belimumab Taking belimumab after rituximab may help lupus according to data from the BEAT-LUPUS trial presented at the 2021 EULAR Virtual Congress by the trial lead investigator […] READ MORE
Updated March 11, 2022 Neuropsychiatric lupus affects 80-90% of people with lupus. In a video series hosted by the Young Leaders Board of the Lupus Research Alliance, Dr. Meggan Mackay explains How to know if you have neuropsychiatric lupus and offers ways to improve cognitive health. Dr. Mackay also describes a clinical trial she is […] READ MORE
Results of clinical trials testing potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2020. These studies include phase I trials, which test for side effects and a safe dosage; larger phase II trials, which test for effectiveness and further gauge safety; and large phase III trials, which confirm […] READ MORE
October 22, 2020 Aurinia Pharmaceuticals announced that data taken from a combined analysis of two trials, AURA-LV and AURORA underscored the potential for voclosporin to offer a tool to treat lupus nephritis. Results from 534 patients from both trials was presented at the American Society of Nephrology Kidney Week 2020 meeting by Dr. Brad Rovin, […] READ MORE
October 22, 2020 Great event; I learned a lot and will have a discussion with my doctor about participating in a trial. It was excellent, and the website is very easy to use. I learned that the medicines you take for lupus are not designed for the disease while the ones you take in a […] READ MORE
July 27, 2020 The Lupus Research Alliance congratulates 2018 Lupus Insight Prize recipient Betty Diamond, MD and the Feinstein Institutes for Medical Research on being awarded $15 million from the National Institute of Allergy and Infectious Disease to study brain dysfunction linked to lupus. Dr. Diamond will use the five-year grant to study a receptor […] READ MORE
December 18, 2019 The Lupus Research Alliance (LRA) welcomes additional positive results published today in the New England Journal of Medicine online edition from AstraZeneca’s Phase 3 TULIP-2 trial studying the investigational biologic anifrolumab as a treatment for systemic lupus erythematosus (SLE or lupus). The new study provides further details showing that anifrolumab, which targets […] READ MORE
